Table 1 Demographic characteristics of all subjects combined and stratified by macular neovascularization (MNV) type

Mean age (95% CI), years

78 (76.14–80.46)

77.44 (74.38–80.5)

80 (76.25–83.75)

78.2 (73.59–82.81)

Sex, male/female

14/28

9/16

4/9

1/4

Mean follow-up (95% CI), years

2.09 (1.8–2.38)

2.01 (1.67–2.35)

2.49 (1.79–3.19)

1.55 (1.04–2.06)

Mean anti-VEGF injections (95% CI), n

10.58 (8.07–13.09)

10.31 (7.4–13.22)

10.93 (6.14–18.52)

8 (3.12–12.88)

Anti-VEGF agent, n

 Aflibercept

18

12

5

1

 Bevacizumab

7

5

1

1

 Ranibizumab

5

1

2

2

 Combination

14

7

6

1

Mean visual acuity, logMAR

 Baseline

0.691

0.549

1.110

0.426

 Endpoint

0.733

0.620

1.147

0.329